• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Vulvar Cancer - Pipeline Review, H2 2012 Product Image

Vulvar Cancer - Pipeline Review, H2 2012

  • ID: 2298859
  • October 2012
  • 46 pages
  • Global Markets Direct

Vulvar Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Vulvar Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vulvar Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vulvar Cancer. Vulvar Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vulvar Cancer.
- A review of the Vulvar Cancer products under development by companies and universities/research institutes based on information READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Vulvar Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Vulvar Cancer 7
Vulvar Cancer Therapeutics under Development by Companies 9
Vulvar Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Vulvar Cancer Therapeutics – Products under Development by Companies 15
Vulvar Cancer Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Vulvar Cancer Therapeutics Development 17
ISA Pharmaceuticals B.V. 17
Vulvar Cancer – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
imiquimod - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
erlotinib hydrochloride - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Avastin + Radiation Therapy - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
docetaxel - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cisplatin + Radiation Therapy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
paclitaxel - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Imiquimod + TA-CIN Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 32
Triapine + Cisplatin + Radiation Therapy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
topotecan hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HPV-SLP Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Carboplatin + Gemcitabine Hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Vulvar Cancer Therapeutics – Drug Profile Updates 39
Vulvar Cancer Therapeutics – Discontinued Products 40
Vulvar Cancer Therapeutics - Dormant Products 41
Vulvar Cancer – Product Development Milestones 42
Featured News & Press Releases 42
Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 42
Apr 26, 2011: Merck Receives Health Canada Approval For Gardasil For Women Up To Age 45 42
Apr 06, 2011: U.S. Prescribing Information for GARDASIL Updated; Indication Not Granted for Use in Adult Women 43
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 43
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 44
Oct 16, 2009: FDA Approves GARDASIL for Use in Boys and Young Men 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Vulvar Cancer, H2 2012 7
Products under Development for Vulvar Cancer – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
ISA Pharmaceuticals B.V., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Vulvar Cancer Therapeutics – Drug Profile Updates 39
Vulvar Cancer Therapeutics – Discontinued Products 40
Vulvar Cancer Therapeutics – Dormant Products 41

List of Figures
Number of Products under Development for Vulvar Cancer, H2 2012 7
Products under Development for Vulvar Cancer – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos